Skip to content

Allphase Pharma Consulting, LLC

A Professional Service Provider for the Pharma Industry

Allphase Pharma Consulting, LLC
Menu
Secondary Menu

Primary menu

  • CONTACT
  • BLOGS
    • The Viewpoint
    • The News
    • Recent Literature
    • Did you know…?
    • QIDP Antibiotics
  • LEGAL
  • WELCOME

Secondary menu

  • The News
  • The Viewpoint
  • Did you know…?
  • Recent Literature
  • QIDP Antibiotics

Tag Archives: MOR antagonist

Trial Pains Secondary to Placebo Effect?

Posted on June 9, 2014 by Harald — No Comments ↓

An interesting report has just been published showing that Naloxegol is beneficial in OIC [i].  Naloxegol is a µ opioid receptor (MOR) antagonist which – by virtue of pegylation – acts peripherally and not centrally.  Hence, the analgesic effects of Continue reading Trial Pains Secondary to Placebo Effect?→

Share this:

  • Click to share on LinkedIn (Opens in new window) LinkedIn
  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on X (Opens in new window) X
  • Click to print (Opens in new window) Print
  • Click to email a link to a friend (Opens in new window) Email

Like this:

Like Loading...
Posted in The Viewpoint | Tagged alvimopan, Amitiza, enrollment dynamics, Entereg, FDA Guidance, lubiprostone, MOR antagonist, Movantik, naloxegol, OIC, opioid side effect, opioid-induced constipation, peripheral opioid antagonist, Phase 3, placebo effect, SBM, study size | Leave a reply

Primary Sidebar Widget Area

Posts and Blogs

  • COMPARISON OF BAFF / APRIL INHIBITORS – 2
  • COMPARISON OF BAFF / APRIL INHIBITORS
  • TELITACICEPT IN SLE
  • The Antifungal Landscape – 2
  • The Antifungal Landscape – 1
  • About DIPHTHERIA
  • Draft FDA Guidance for COCCIDIOIDOMYCOSIS
  • HANSA, Where is the Beef?
  • OLOROFIM in a TIGHT SPOT
  • Prof Brambell’s FcRn – The Story So Far

Subscribe to AllphasePharma Blogs via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Tags

ABSSSI Achaogen Allphase Pharma Consulting aminoglycoside antibiotic blog Avycaz Bayer CABP Ceftazidime/avibactam cIAI ciprofloxacin colistin Cubicin Cubist cUTI dalbavancin Dalvance daptomycin delafloxacin eravacycline FDA fosfomycin GSK Harald Reinhart levofloxacin Merck meropenem moxifloxacin MRSA Novartis omadacycline oritavancin P. aeruginosa Pfizer PK/PD plazomicin QIDP solithromycin tedizolid tetracycline Tetraphase tigecycline Tygacil vancomycin VAP

Footer menu

  • CONTACT
  • BLOGS
  • LEGAL
  • WELCOME
  • Email
Copyright © 2025 Allphase Pharma Consulting, LLC. All Rights Reserved.
Theme: Catch Box by Catch Themes
Scroll Up
%d